Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Income Statement [Abstract]    
Sales      
Cost of sales     
Gross profit      
Operating Expenses:    
General and adminstrative expenses 3,283,490 2,064,154
Research and development expenses 17,499 489,345
Total Operating Expenses 3,300,989 2,553,499
Income (Loss) from operations (3,300,989) (2,553,499)
Interest expense (3,341,981) (5,231,231)
Change in fair market value of derivative liability (4,526,688) 153,540
Loss on disposal of assets 470,454   
Loss from continuing operations before provision for income taxes (11,640,112) (7,631,190)
Provision for income taxes      
Loss from continuing operations (11,640,112) (7,631,190)
Loss from discontinued operations, net of taxes (8,648,381) (333,412)
Loss on sale of assets 666,592   
Net loss (19,621,901) (7,964,602)
Deemed dividend on preferred stock (4,136,003)   
Net loss attributable to Biozone $ (23,757,904) $ (7,964,602)
Loss per common share - continuing operations $ (0.22) $ (0.12)
Loss per common share - discontinued operations $ (0.11) $ (0.01)
Loss per common share $ (0.33) $ (0.13)
Basic and diluted weighted average common share outstanding 72,500,136 61,631,047